CIP-36, a novel podophyllotoxin derivative, induces the apoptosis of KBV200 cells

Chinese Pharmacological Bulletin

Volumn 26, Issue 5, 2010, Pages 607-610

  Lü, Jing Jing ^a   Zhang, Yu Yang ^a   Chen, Hong ^b   Cao, Bo ^b   Zhang, Yuan ^b   Lu, Yan Ling ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard   (China)

Author keywords

Cell cycle; CIP 36; Microtubule; P glycoprotein; Podophyllotoxin derivative

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CIP 36; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CYTOSKELETON; DRUG MECHANISM; FEASIBILITY STUDY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; IN VITRO STUDY; MICROTUBULE ASSEMBLY; MORPHOLOGY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 77956799278     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Issell B F. The podophyllotoxin derivatives VP16-213 and VM26 [J]. Cancer Chemother Pharmacol, 1982,7(2-3):73-80.
2. Lum B L, Kaubisch S, Yahanda A M, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance [J]. J Clin Oncol, 1992,10(10):1635-42. (Pubitemid 23057994)
3. Ji S Y, Weng Z Y, Zhou T P, et al. The cytotoxicity of some organic solvents in common use on human tumor cell lines [J]. J Yunnan Univ Nat Sci, 2001,23(6):457-60.
4. Bacher G, Nickel B, Emig P, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows eficacy toward muhidrug-resistant tumor cells, and lacks neurotoxicity [J]. Cancer Res, 2001,61(1):392-9. (Pubitemid 32106651)
5. Wang H, Lei Z Y, Chen H, et al. Antitumor activity of PB-LY and its mechanism in vitro[J]. Chin Pharmacol Bull, 2008,24(9):1204-8.
6. Yu T, Zhao G S, Zang H C, et al. Advances in tumor multidrug resistance reversal agents [J]. Chin J Med Chem, 2003,13(3):172-8.
7. Marzolini C, Paus E, Buclin T, et al. Polymophisma in human MDR1 (P-glycoprotein): recent advances and clinical relevance [J]. Clin Pharmacol Ther, 2004,75(1):13-33. (Pubitemid 38130115)
8. Kiselyov A, Balakin K V, Tkachenko S E, et al. Recent progress in discovery and development of antimitotic agents[J]. Anticancer Agents Med Chem, 2007,7(2):189-208. (Pubitemid 46403584)
9. Fumoleau P, Coudert B, Isambert N. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues[J]. Ann Oncol, 2007,18(5):9-15.